BRIEF—Idorsia's Quviviq now covered by CVS

Switzerland-headquartered Idorsia and its US subsidiary today announced that, effective immediately, pharmacy benefit managers (PBM) CVS is covering Quviviq (daridorexant) CIV on the Performance Drug List (PDL).

Around 20 million people are enrolled in this CVS plan, providing increased access to Quviviq for the millions of adults who can benefit from this latest prescription insomnia therapy.

Quviviq is now covered by two of the largest insurance plans in the USA, Express Scripts and CVS, and several associated regional plans, as well as TRICARE, the healthcare program for active and retired US military personnel and their families.

Quviviq was approved in January 2022 for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Since availability of the product in May 2022, Quviviq has quickly gained traction with patients and physicians, and more than 180,000 prescriptions have been dispensed to date, Idorsia pointed out.